PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1836293
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1836293
Newborn screening market size was valued at US$ 861.67 Million in 2024, expanding at a CAGR of 8.01% from 2025 to 2032.
Newborn screening is a public health program designed to identify genetic, metabolic, hormonal, and functional disorders in infants shortly after birth. Conducted through simple blood, hearing, and heart tests, it helps detect conditions that may not be visible at birth but can cause serious health issues if left untreated. Early diagnosis through newborn screening enables timely treatment and intervention, preventing disability, promoting healthy development, and improving survival rates in newborns.
Newborn Screening Market- Market Dynamics
Increasing surge in congenital disorders among newborns to propel market demand
An expanding neonatal population, the surge in congenital disorders among newborns, rising parental awareness, and supportive government programs and legislations are anticipated to drive market growth during the forecast period. Moreover, continuous innovations and advancements in screening technologies are likely to further accelerate the market's expansion. However, high cost of advanced technologies limits accessibility, as next-generation sequencing and MS/MS implementation remain prohibitively expensive, especially for developing regions. On the contrary, government investments in genomic screening and expansion of screening panels presents major growth opportunities for the global newborn screening market.
The Global Newborn Screening Market is segmented on the basis of Product, Test Type, Technology, End User, and Region.
The market is divided into two categories based on Product: reagents and instruments. The reagents segment is expected to hold the major market share during the forecast period. This dominance is primarily due to their recurring demand in every screening test, unlike instruments which are purchased once and used over longer cycles.
The market is divided into six categories based on Technology: tandem mass spectrometry, enzyme-based assay, electrophoresis, pulse oximetry, DNA assay, and others. Among these, the tandem mass spectrometry (TMS) is expected to hold the major market share during the forecast period. Its ability to simultaneously detect multiple metabolic and genetic disorders with high accuracy and sensitivity has made it the most preferred technology.
Growing focus on early detection of genetic and metabolic disorders is driving companies to enhance their product offerings with advanced screening technologies. Market players are emphasizing strategic collaborations, government partnerships, and investments in research to expand their portfolios. Many are adopting automation, AI-driven diagnostic tools, and miniaturized testing devices to improve accuracy and efficiency. Additionally, firms are strengthening their presence in emerging economies by offering cost-effective solutions and expanding distribution networks, while also focusing on regulatory approvals to ensure faster adoption.
In August 2025, Sidra Medicine, a Qatar Foundation member, has partnered with Rady Children's Institute for Genomic Medicine (RCIGM(R)) to implement the genome-based newborn screening research program, BeginNGS. As the first international site in the consortium, Sidra Medicine aims to advance early detection of genetic diseases and support timely interventions to reduce childhood suffering.